BTIG analyst Marie Thibault reiterated a Buy rating on Outset Medical yesterday and set a price target of $15.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Marie Thibault has given his Buy rating due to a combination of factors that highlight improving business visibility and growth potential. Outset Medical delivered quarterly revenue and gross margin that exceeded prior expectations, supported by a high proportion of stable, recurring revenue and a more disciplined approach to forecasting its console pipeline.
In addition, the newly cleared next-generation Tablo system, with enhanced cybersecurity and performance features, is expected to support stronger demand and future expansion, particularly among hospital customers. When combined with a growing and diversified pipeline, better margin trajectory, lower anticipated cash burn, and a valuation based on a modest 2x EV/sales multiple leading to a $15 price target, these dynamics underpin Thibault’s continued Buy recommendation.
In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $12.00 price target.